We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase 1 Study of MKC-1 in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00656461
Recruitment Status : Completed
First Posted : April 11, 2008
Last Update Posted : November 25, 2009
Information provided by:
CASI Pharmaceuticals, Inc.

Brief Summary:
This is an open-label study to determine the highest dose of MKC-1 that may be administered daily on a continuous basis for patients with advanced or refractory solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Cancer Drug: MKC-1 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of MKC-1 in Patients With Advanced or Metastatic Solid Malignancies
Study Start Date : March 2008
Primary Completion Date : July 2009
Study Completion Date : November 2009

Arm Intervention/treatment
Experimental: 1 Drug: MKC-1
30 mg and 100 mg capsules, dosed BID daily on a continuous schedule

Primary Outcome Measures :
  1. Determine the maximum tolerated dose (MTD) of MKC-1 administered orally twice a day (bid) continuously in patients with advanced or refractory solid tumors. [ Time Frame: Throughout study participation ]

Secondary Outcome Measures :
  1. Determine evidence of benefit in cancer patients when MKC-1 is administered orally twice a day (bid) continuously by evaluating tumor response and/or tumor marker improvement. [ Time Frame: During study participation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective.
  • Age greater than or equal to 18 years.
  • ECOG performance status ≤1
  • ANC greater than or equal to 1,500/mm3;
  • Platelets greater than or equal to 100,000/mm3
  • creatinine ≤1.5 times institutional upper limit of normal (ULN)
  • T Bili within normal limits;
  • AST and ALT less than or equal to 2.5 times ULN; and
  • albumin greater than or equal to 3.0 g/dL
  • have measurable disease by RECIST, radiographically evaluable disease, or detectable disease
  • women of child-bearing potential and men must agree to use adequate contraception
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Have previously received MKC-1.
  • Have received radiation to greater than 25% of the bone marrow.
  • Have had anti-cancer therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Are concurrently receiving any other investigational agents while on study.
  • Have known brain metastases
  • Have any condition that impairs the ability to swallow and retain MKC-1 capsules.
  • Uncontrolled intercurrent illness
  • Are pregnant or breastfeeding
  • HIV-positive patients
  • Patients with uncontrolled diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00656461

United States, Wisconsin
U. of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
CASI Pharmaceuticals, Inc.
Principal Investigator: Glenn Liu, MD U. of Wisconsin

Responsible Party: Chief Medical Officer, Miikana Therapeutics, an EntreMed, Inc. company
ClinicalTrials.gov Identifier: NCT00656461     History of Changes
Other Study ID Numbers: MKC-106
First Posted: April 11, 2008    Key Record Dates
Last Update Posted: November 25, 2009
Last Verified: November 2009

Keywords provided by CASI Pharmaceuticals, Inc.:
Advanced cancer

Additional relevant MeSH terms: